Is it possible that Pfizer needs Olinvyk as much as Trevena needs Pfizer?
Who wants to partner or allow a buyout?Trevena already has a significant cash run way to 2023, a newly approved large addressable market, licensing agreements w/ China and S. Korea, patent applications pending in Europe, Japan, Israel, etc., and a manufacturing agreement w/ Pfizer who has been in active production of Olinvyk for months.
At the appropriate valuation, of course, a small biotech like Trevena would like to partner from sale and distribution. But ONLY with acceptable terms and conditions. |
Who needs to "cut that deal"?As the title of the article states above, "Pfizer, The Share That Can't Stop Feeding". This brings to mind the question, is it that Pfizer can't stop feeding because it doesn't want to ... or that it can't stop eating because if it slows down, so will it's 6% target rate of growth. Slowing growth endangers shareholders dividends.
With today's headlines (2020.08.25) reading, "Dow kicks out Pfizer", "Pfizer Just Got Booted from the Dow", and "Pfizer Got Kicked Off the Dow Just as Things Were Looking Up", who really needs who more??? |
Question: How long will a buyout take to consummate, if one should occur?
Answer: Longer than many may assume.
The company that is the subject of the takeover or merger must file a Schedule 14D-9 with the SEC.
Another ST user pointed out that this typically takes 2 to 4 months.
If PFE is in talks w/ TRVN today (Aug. 25th), then we are still 60 to 90 days out from an announcement.
This is not a fast process.
Another ST user pointed out that this typically takes 2 to 4 months.
If PFE is in talks w/ TRVN today (Aug. 25th), then we are still 60 to 90 days out from an announcement.
This is not a fast process.